Subsequent Events	3 Months Ended
Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 11. Subsequent Events The Company has evaluated subsequent events from the balance sheet date through May 17, 2021. The following are material subsequent events: Employment Agreements On April 7, 2021, Virpax Pharmaceuticals, Inc. (the “Company”) entered into employment agreements with each of Christopher Chipman, the Company’s Chief Financial Officer, and Jeffrey Gudin, the Company’s Chief Medical Officer. The agreements have three year terms and provide for annual base salaries and bonuses, as defined. Option Grants On April 7, 2021, the Company’s Board of Directors (the “Board”), upon recommendation of the Company’s compensation committee (the “Compensation Committee”), approved equity compensation awards for the Company’s executive officers and directors. The Board approved awards of options (the “Options”) to purchase 150,000 shares of Common Stock to officers of the Company pursuant to the 2017 PlanThe Options have an exercise price of $4.62 per share, the fair market value of the Common Stock on the date of grant of April 7, 2021. The Options granted to the officers will vest in three equal annual installments, commencing on the one year anniversary of the grant date, and have a ten year expiration date. The Board also approved awards of 52,922 options to the Company’s non-employee directors pursuant to the 2017 Plan. These Options have exercise prices of $4.62, the fair market value of the common stock on the date of grant of April 7, 2021, will fully vest upon the one year anniversary of the grant date, and have a ten year expiration date. Director Compensation Policy On April 12, 2021, the Compensation Committee recommended to the Board, and the Board approved, changes to the Company’s non-employee director compensation policy whereby each non-employee director will receive an annual cash retainer of $10,000, payable in equal quarterly installments. Restricted Shares On April 7, 2021, the Company granted 15,000 shares of restricted common stock that vests in one year from the grant date to a consultant.

Subsequent Events

3 Months Ended

Mar. 31, 2021

Note 11. Subsequent Events

The Company has evaluated subsequent events from the balance sheet date through May 17, 2021. The following are material subsequent events:

Employment Agreements

On April 7, 2021, Virpax Pharmaceuticals, Inc. (the “Company”) entered into employment agreements with each of Christopher Chipman, the Company’s Chief Financial Officer, and Jeffrey Gudin, the Company’s Chief Medical Officer. The agreements have three year terms and provide for annual base salaries and bonuses, as defined.

Option Grants

On April 7, 2021, the Company’s Board of Directors (the “Board”), upon recommendation of the Company’s compensation committee (the “Compensation Committee”), approved equity compensation awards for the Company’s executive officers and directors.

The Board approved awards of options (the “Options”) to purchase 150,000 shares of Common Stock to officers of the Company pursuant to the 2017 PlanThe Options have an exercise price of $4.62 per share, the fair market value of the Common Stock on the date of grant of April 7, 2021. The Options granted to the officers will vest in three equal annual installments, commencing on the one year anniversary of the grant date, and have a ten year expiration date.

The Board also approved awards of 52,922 options to the Company’s non-employee directors pursuant to the 2017 Plan. These Options have exercise prices of $4.62, the fair market value of the common stock on the date of grant of April 7, 2021, will fully vest upon the one year anniversary of the grant date, and have a ten year expiration date.

Director Compensation Policy

On April 12, 2021, the Compensation Committee recommended to the Board, and the Board approved, changes to the Company’s non-employee director compensation policy whereby each non-employee director will receive an annual cash retainer of $10,000, payable in equal quarterly installments.

Restricted Shares

On April 7, 2021, the Company granted 15,000 shares of restricted common stock that vests in one year from the grant date to a consultant.